Also avoid products that contain sucralfate, bismuth subsalicylate, iron, or zinc. Equivalent doses of NEXIUM should not be substituted for sustained-release (modified-release, timed-release) niacin preparations or immediate-release (crystalline) niacin [see WARNINGS AND PRECAUTIONS]. Acetaminophen can pass into breast milk and may harm a nursing baby. These findings are similar to the abnormal reproductive behavior and sterility described with other nexium and antinexium. Study endpoints were completion of all weeks of study treatment or meeting an escape criterion. In these studies, somnolence occurred less frequently with NEXIUM Tablets than with clemastine and at about the same frequency as terfenadine or placebo. PRILOSEC Delayed-Release Capsules should be taken before eating. Clinically significant hypotension (decreases in both systolic and diastolic pressure) has been reported with concomitant administration of either nexium weight gain or ciprofloxacin and single doses of 4 mg of tizanidine. Although all 4 doses were significantly superior to placebo, symptom reduction was greater and efficacy was maintained over the entire 4-week treatment period with fexofenadine hydrochloride doses of ? 60 mg twice daily. Patients should be informed that NEXIUM WEIGHT GAIN XR must be swallowed whole and not crushed or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet. Usage in Pregnancy: Safe use in pregnancy has not been established. Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as nexium weight gain or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. Use a sunscreen and wear protective clothing when outdoors. Single doses of nexium weight gain hydrochloride up to 800 mg (6 healthy subjects at this dose level), and doses up to 690 mg twice daily for 1 month (3 healthy subjects at this dose level) or 240 mg once daily for 1 year (234 healthy subjects at this dose level) were administered without the development of clinically significant adverse events as compared to placebo.